Histone Deacetylase 6 - Pipeline Review, H2 2020
Histone Deacetylase 6 - Pipeline Review, H2 2020
SUMMARY
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Histone deacetylase 6 is an enzyme encoded by the HDAC6 gene. Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases plays a central role in microtubule-dependent cell motility via deacetylation of tubulin. It is involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer. It plays a key role in the degradation of misfolded proteins. It acts as an adapter that recognizes polyubiquitinated misfolded proteins and target them to the aggresome, facilitating their clearance by autophagy.
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) pipeline Target constitutes close to 52 molecules. Out of which approximately 43 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 6, 3, 1, 27 and 6 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively.
Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Immunology, Toxicology, Gastrointestinal, Genito Urinary System And Sex Hormones, Infectious Disease, Metabolic Disorders, Musculoskeletal Disorders, Respiratory and Undisclosed which include indications Multiple Myeloma (Kahler Disease), Melanoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alzheimer's Disease, Charcot-Marie-Tooth Disease, Solid Tumor, Triple-Negative Breast Cancer (TNBC), Breast Cancer, Charcot-Marie-Tooth Disease Type II, Chemotherapy Induced Peripheral Neuropathy, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme (GBM), Multiple Sclerosis, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia (CLL), Colon Cancer, Follicular Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Leukemia, Mantle Cell Lymphoma, Rheumatoid Arthritis, Squamous Cell Carcinoma, Systemic Lupus Erythematosus, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenoid Cystic Carcinoma (ACC), Amyotrophic Lateral Sclerosis, Anal Cancer, Autoimmune Disorders, B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Bile Duct Cancer (Cholangiocarcinoma), Blood Cancer, Burkitt Lymphoma, Cervical Cancer, Chronic Kidney Disease (Chronic Renal Failure), CNS Lymphoma, Crohn's Disease (Regional Enteritis), Cutaneous T-Cell Lymphoma, Diabetic Neuropathic Pain, Diabetic Peripheral Neuropathy, Fibrosis, Gallbladder Cancer, Gastric Cancer, Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, High-Grade Glioma, Human Papillomavirus (HPV) Associated Cancer, Huntington Disease, Idiopathic Pulmonary Fibrosis, Liver Cancer, Lung Adenocarcinoma, Lupus Nephritis, Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Biliary Tract Cancer, Mycosis Fungoides, Myelodysplastic Syndrome, Neuroblastoma, Neurology, Neuropathic Pain (Neuralgia), Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Pediatric Diffuse Intrinsic Pontine Glioma, Penile Cancer, Polycystic Kidney Disease, Prostate Cancer, Rectal Cancer, Recurrent Medulloblastoma, Rett Syndrome, Sepsis, Tauopathies, Ulcerative Colitis, Unspecified and Vulvar Cancer.
The latest report Histone Deacetylase 6 - Pipeline Review, H2 2020, outlays comprehensive information on the Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Histone deacetylase 6 is an enzyme encoded by the HDAC6 gene. Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases plays a central role in microtubule-dependent cell motility via deacetylation of tubulin. It is involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer. It plays a key role in the degradation of misfolded proteins. It acts as an adapter that recognizes polyubiquitinated misfolded proteins and target them to the aggresome, facilitating their clearance by autophagy.
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) pipeline Target constitutes close to 52 molecules. Out of which approximately 43 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 6, 3, 1, 27 and 6 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively.
Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Immunology, Toxicology, Gastrointestinal, Genito Urinary System And Sex Hormones, Infectious Disease, Metabolic Disorders, Musculoskeletal Disorders, Respiratory and Undisclosed which include indications Multiple Myeloma (Kahler Disease), Melanoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alzheimer's Disease, Charcot-Marie-Tooth Disease, Solid Tumor, Triple-Negative Breast Cancer (TNBC), Breast Cancer, Charcot-Marie-Tooth Disease Type II, Chemotherapy Induced Peripheral Neuropathy, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme (GBM), Multiple Sclerosis, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia (CLL), Colon Cancer, Follicular Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Leukemia, Mantle Cell Lymphoma, Rheumatoid Arthritis, Squamous Cell Carcinoma, Systemic Lupus Erythematosus, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenoid Cystic Carcinoma (ACC), Amyotrophic Lateral Sclerosis, Anal Cancer, Autoimmune Disorders, B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Bile Duct Cancer (Cholangiocarcinoma), Blood Cancer, Burkitt Lymphoma, Cervical Cancer, Chronic Kidney Disease (Chronic Renal Failure), CNS Lymphoma, Crohn's Disease (Regional Enteritis), Cutaneous T-Cell Lymphoma, Diabetic Neuropathic Pain, Diabetic Peripheral Neuropathy, Fibrosis, Gallbladder Cancer, Gastric Cancer, Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, High-Grade Glioma, Human Papillomavirus (HPV) Associated Cancer, Huntington Disease, Idiopathic Pulmonary Fibrosis, Liver Cancer, Lung Adenocarcinoma, Lupus Nephritis, Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Biliary Tract Cancer, Mycosis Fungoides, Myelodysplastic Syndrome, Neuroblastoma, Neurology, Neuropathic Pain (Neuralgia), Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Pediatric Diffuse Intrinsic Pontine Glioma, Penile Cancer, Polycystic Kidney Disease, Prostate Cancer, Rectal Cancer, Recurrent Medulloblastoma, Rett Syndrome, Sepsis, Tauopathies, Ulcerative Colitis, Unspecified and Vulvar Cancer.
The latest report Histone Deacetylase 6 - Pipeline Review, H2 2020, outlays comprehensive information on the Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)
- The report reviews Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
- The report assesses Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Overview
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Therapeutics Development
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Therapeutics Assessment
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Drug Profiles
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Dormant Products
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Product Development Milestones
Appendix
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Overview
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Therapeutics Development
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Therapeutics Assessment
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Drug Profiles
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Dormant Products
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Annji Pharmaceutical Co Ltd, H2 2020
Pipeline by ATP Biopharm, H2 2020
Pipeline by Augustine Therapeutics, H2 2020
Pipeline by Bristol-Myers Squibb Co, H2 2020
Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2020
Pipeline by Convalife, H2 2020
Pipeline by CStone Pharmaceuticals Co Ltd, H2 2020
Pipeline by Curis Inc, H2 2020
Pipeline by Eikonizo Therapeutics Inc, H2 2020
Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, H2 2020
Dormant Products, H2 2020
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Annji Pharmaceutical Co Ltd, H2 2020
Pipeline by ATP Biopharm, H2 2020
Pipeline by Augustine Therapeutics, H2 2020
Pipeline by Bristol-Myers Squibb Co, H2 2020
Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2020
Pipeline by Convalife, H2 2020
Pipeline by CStone Pharmaceuticals Co Ltd, H2 2020
Pipeline by Curis Inc, H2 2020
Pipeline by Eikonizo Therapeutics Inc, H2 2020
Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, H2 2020
Dormant Products, H2 2020
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
